|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||47.8 kg/mol g·mol−1|
This drug was developed by Boehringer Ingelheim Pharmaceuticals. A study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes. It was FDA approved in October 2015. In the United States the wholesale cost is $3500 US.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab, American Medical Association.
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- Pollack, Charles V.; Reilly, Paul A.; Eikelboom, John; Glund, Stephan; Verhamme, Peter; Bernstein, Richard A.; Dubiel, Robert; Huisman, Menno V.; Hylek, Elaine M. (2015-08-06). "Idarucizumab for Dabigatran Reversal". The New England Journal of Medicine. 373 (6): 511–520. doi:10.1056/NEJMoa1502000. ISSN 1533-4406. PMID 26095746.
- "Press Announcements - FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa". www.fda.gov. Retrieved 2015-10-17.
- Elia, Joe. "Dabigatran-Reversal Agent Price Set". Retrieved 20 October 2015.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|